HC Wainwright & Co. Reiterates Buy on Maze Therapeutics, Maintains $110 Price Target
HC Wainwright & Co. analyst Ananda Ghosh reiterates Maze Therapeutics (NASDAQ:MAZE) with a Buy and maintains $110 price target.
Stocks · News reference
8-K filing — Maze Therapeutics, Inc. (MAZE)
Filed: 2026-08-17 AccNo: 0001193125-26-354092 Size: 175 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Citigroup Initiates Coverage On Maze Therapeutics with Buy Rating, Announces Price Target of $50
Citigroup analyst Eric Joseph initiates coverage on Maze Therapeutics (NASDAQ:MAZE) with a Buy rating and announces Price Target of $50.
TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday
U.S. stocks fell as Nasdaq dropped 100+ points, while TriSalus surged 5.8% on FDA clearance; Securitize, Lakefront and others also gained.
Wedbush Reiterates Outperform on Maze Therapeutics, Maintains $48 Price Target
Wedbush analyst Laura Chico reiterates Maze Therapeutics (NASDAQ:MAZE) with a Outperform and maintains $48 price target.